1 Min Read
June 8 (Reuters) - Endo International Plc:
* Endo response to june 8, 2017 FDA meeting related to opana® er
* Endo international plc- "endo is reviewing request and is evaluating full range of potential options as we determine appropriate path forward"
* Endo - fda's request to withdraw opana er from market does not indicate uncertainty with product's safety or efficacy when taken as prescribed Source text for Eikon: Further company coverage: